WR Hambrecht & Co. has predicted a "monster" third quarter for Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) , powered by Zoloft and Zocor.
Teva is included in a new industry update ahead of the publication of financial results for the third quarter, which saysthat “the broad product line and developmental pipeline is robust and will sustain an equally robust growth in the near term”, and gives the share a “Buy” recommendation.
WR Hambrecht predicts that Teva will report $0.58 earning per share for the third quarter on $2.27 billion revenue, up “an astounding 72% year over year”. The forecast is conservative and below the market consensus of $0.63 earning per share on $2.33 billion revenue.
WR Hambrecht predicts that Teva’s sales in North America will total $1.28 billion for the third quarter, 81% more than for the corresponding quarter of last year, but adds, “We strongly suspect Zocor and Zoloft sales will push the numbers higher than our estimates”. Outside the US, the investment bank predicts $523 million in sales in Europe, up 53% on the corresponding quarter, and $275 million in sales in the rest of the world, up 21% on the corresponding quarter. Third quarter Copaxone sales are predicted to total $365 million, 3.4% more than for the preceding quarter and 19% more than for the corresponding quarter.
WR Hambrecht nevertheless predicts that Teva’s gross margin will be 50% for the third quarter, down 5.4% compared with the preceding quarter.
Published by Globes [online], Israel business news - www.globes.co.il - on October 17, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006